Can-Fite BioPharma Ltd.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- CANFCan-Fite BioPharma0Calm
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Signing up patientsPhase 3471 patientsMain results: Feb 2026 - CANFCan-Fite BioPharma0Calm
Namodenoson Treatment of Advanced Pancreatic Cancer
Signing up patientsPhase 220 patientsMain results: Jul 15, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
No insider sales or purchases in the last 6 months.
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- None in the last 12 months.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.